Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Laura L Hammitt, MD"'
Autor:
John Ojal, PhD, Ulla Griffiths, PhD, Laura L Hammitt, MD, Ifedayo Adetifa, PhD, Donald Akech, BSc, Collins Tabu, PhD, J Anthony G Scott, FRCP, Stefan Flasche, PhD
Publikováno v:
The Lancet Global Health, Vol 7, Iss 5, Pp e644-e654 (2019)
Summary: Background: In 2009, Gavi, the World Bank, and donors launched the pneumococcal Advance Market Commitment, which helped countries access more affordable pneumococcal vaccines. As many low-income countries begin to reach the threshold at whic
Externí odkaz:
https://doaj.org/article/be463c7239c840f598254e9dca2c0036
Autor:
Micah Silaba, MMed, Michael Ooko, MSc, Christian Bottomley, PhD, Joyce Sande, MMed, Rachel Benamore, FRCR, Kate Park, FRCR, James Ignas, MD, Kathryn Maitland, FMedSci, Neema Mturi, MMed, Anne Makumi, MSc, Mark Otiende, MSc, Stanley Kagwanja, Dip MIS, Sylvester Safari, Dip MIS, Victor Ochola, BSc, Tahreni Bwanaali, MBA, Evasius Bauni, PhD, Fergus Gleeson, FRCR, Maria Deloria Knoll, PhD, Ifedayo Adetifa, PhD, Kevin Marsh, FMedSci, Thomas N Williams, FMedSci, Tatu Kamau, MPH, Shahnaaz Sharif, MD, Orin S Levine, PhD, Laura L Hammitt, MD, J Anthony G Scott, FMedSci
Publikováno v:
The Lancet Global Health, Vol 7, Iss 3, Pp e337-e346 (2019)
Summary: Background: Pneumococcal conjugate vaccines (PCV) are highly protective against invasive pneumococcal disease caused by vaccine serotypes, but the burden of pneumococcal disease in low-income and middle-income countries is dominated by pneum
Externí odkaz:
https://doaj.org/article/541affacefca48658490fc034546777d
Autor:
Dr. Laura L Hammitt, MD, Rosie J Crane, MBBS, Angela Karani, BSc, Alex Mutuku, MSc, Susan C Morpeth, FRACP, Polly Burbidge, BSc, Prof. David Goldblatt, MB ChB, Tatu Kamau, MPH, Shahnaaz Sharif, MD, Neema Mturi, MRCPCH, Prof. J Anthony G Scott, FRCP
Publikováno v:
The Lancet Global Health, Vol 4, Iss 3, Pp e185-e194 (2016)
Background: Haemophilus influenzae type b (Hib) conjugate vaccine, delivered as a three-dose series without a booster, was introduced into the childhood vaccination programme in Kenya in 2001. The duration of protection and need for a booster dose ar
Externí odkaz:
https://doaj.org/article/fb6be273a4874e1db40c7d004e5d4b43
Autor:
Dr. Laura L Hammitt, MD, Donald O Akech, BSc, Susan C Morpeth, FRACP, Angela Karani, BSc, Norbert Kihuha, BSc, Sammy Nyongesa, MSc, Tahreni Bwanaali, MBA, Edward Mumbo, BSc, Tatu Kamau, MPH, Shahnaaz K Sharif, MD, Prof. J Anthony G Scott, FRCP
Publikováno v:
The Lancet Global Health, Vol 2, Iss 7, Pp e397-e405 (2014)
Background: The effect of 7-valent pneumococcal conjugate vaccine (PCV) in developed countries was enhanced by indirect protection of unvaccinated individuals, mediated by reduced nasopharyngeal carriage of vaccine-serotype pneumococci. The potential
Externí odkaz:
https://doaj.org/article/96f9f97b804b4edca46eb2955d89aab4